Skip to main content
Erschienen in: Reactions Weekly 1/2019

01.03.2019 | Case report

Bufexamac/chlorhexidine/lidocaine

Allergic contact dermatitis and drug eruptions: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Harris AG, et al. Severe cutaneous eruptions following the topical use of preparations containing bufexamac: Is it time to reconsider its registration in Australia?. Australasian Journal of Dermatology 60: 53-56, No. 1, Feb 2019. Available from: URL: http://doi.org/10.1111/ajd.12910 - AustraliaCrossRefPubMed Harris AG, et al. Severe cutaneous eruptions following the topical use of preparations containing bufexamac: Is it time to reconsider its registration in Australia?. Australasian Journal of Dermatology 60: 53-56, No. 1, Feb 2019. Available from: URL: http://​doi.​org/​10.​1111/​ajd.​12910 - AustraliaCrossRefPubMed
Metadaten
Titel
Bufexamac/chlorhexidine/lidocaine
Allergic contact dermatitis and drug eruptions: 3 case reports
Publikationsdatum
01.03.2019
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-58970-x

Weitere Artikel der Ausgabe 1/2019

Reactions Weekly 1/2019 Zur Ausgabe

Case report

Aspirin

Case report

Iron overdose

Case report

Paracetamol

Case report

Methotrexate

Case report

Remifentanil